SNM intends to deliver and scan the phantom at an additional 20 imaging centers by the end of September.
SNM's Clinical Trials Network evaluates images produced by phantoms to ensure that molecular imaging centers are providing consistent and accurate images. SNM notes that imaging consistency among sites, both in the technology used and images produced, is critical for ensuring quality imaging and quantitative data and is essential to meet U.S. Food and Drug Administration (FDA) requirements for investigational clinical trials.
Successfully scanning phantoms are one part of the overall process the network will use to validate imaging sites for future clinical trials.
SNM, CMOD plan May PET meeting, March 27, 2009
FDA clears SNM IND application, February 3, 2009
SNM criticizes NAS isotope report, January 16, 2009
SNM creates clinical trials network, October 7, 2008
SNM has 'serious concerns' over isotope situation, August 28, 2008
Copyright © 2009 AuntMinnie.com